Role of Model-Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling
- PMID: 31502691
- DOI: 10.1002/jcph.1478
Role of Model-Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling
Abstract
The unique challenges in pediatric drug development require efficient and innovative tools. Model-informed drug development (MIDD) offers many powerful tools that have been frequently applied in pediatric drug development. MIDD refers to the application of quantitative models to integrate and leverage existing knowledge to bridge knowledge gaps and facilitate development and decision-making processes. This article discusses the current practices and visions of applying MIDD in pediatric drug development, regulatory evaluation, and labeling, with detailed examples. The application of MIDD in pediatric drug development can be broadly classified into 3 categories: leveraging knowledge for bridging the gap, dose selection and optimization, and informing clinical trial design. In particular, MIDD can provide evidence for the assumption of exposure-response similarity in bridging existing knowledge from reference to target population, support the dose selection and optimization based on the "exposure-matching" principle in the pediatric population, and increase the efficiency and success rate of pediatric trials. In addition, the role of physiologically based pharmacokinetics in drug-drug interaction in children and adolescents and in utilizing ontogeny data to predict pharmacokinetics in neonates and infants has also been illustrated. Moving forward, MIDD should be incorporated into all pediatric drug development programs at every stage to inform clinical trial design and dose selection, with both its strengths and limitations clearly laid out. The accumulated experience and knowledge of MIDD has and will continue to drive regulatory policy development and refinement, which will ultimately improve the consistency and efficiency of pediatric drug development.
Keywords: dose selection and optimization; informing clinical trial design; leveraging knowledge; model-informed drug development; pediatric drug development; pediatric ontogeny.
Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
Similar articles
-
Model-Informed Drug Development in Pediatric Dose Selection.J Clin Pharmacol. 2021 Jun;61 Suppl 1:S60-S69. doi: 10.1002/jcph.1848. J Clin Pharmacol. 2021. PMID: 34185906 Review.
-
Model-Informed Drug Development: Current US Regulatory Practice and Future Considerations.Clin Pharmacol Ther. 2019 Apr;105(4):899-911. doi: 10.1002/cpt.1363. Epub 2019 Mar 1. Clin Pharmacol Ther. 2019. PMID: 30653670
-
Industry Perspective on Using MIDD for Pediatric Studies Requiring Integration of Ontogeny.J Clin Pharmacol. 2019 Sep;59 Suppl 1:S112-S119. doi: 10.1002/jcph.1495. J Clin Pharmacol. 2019. PMID: 31502694 Review.
-
Application of Model-Informed Drug Development in Dose Selection and Optimization for siRNA Therapies.J Clin Pharmacol. 2024 Jul;64(7):799-809. doi: 10.1002/jcph.2418. Epub 2024 Mar 1. J Clin Pharmacol. 2024. PMID: 38426370 Review.
-
Opportunities and challenges for applying model-informed drug development approaches to gene therapies.CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):286-290. doi: 10.1002/psp4.12597. Epub 2021 Mar 5. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33608998 Free PMC article. Review.
Cited by
-
Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions.CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1195-1207. doi: 10.1002/psp4.12688. Epub 2021 Aug 23. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34292671 Free PMC article.
-
Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making.Pharm Res. 2022 Aug;39(8):1669-1680. doi: 10.1007/s11095-022-03288-w. Epub 2022 May 12. Pharm Res. 2022. PMID: 35552984 Free PMC article. Review.
-
Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development.AAPS PharmSciTech. 2021 Jul 26;22(6):208. doi: 10.1208/s12249-021-02076-w. AAPS PharmSciTech. 2021. PMID: 34312742 Free PMC article. Review.
-
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan.J Pharmacokinet Pharmacodyn. 2025 Jan 6;52(1):10. doi: 10.1007/s10928-024-09954-3. J Pharmacokinet Pharmacodyn. 2025. PMID: 39762622
-
All You Need to Know About Allometric Scaling: An Integrative Review on the Theoretical Basis, Empirical Evidence, and Application in Human Pharmacology.Clin Pharmacokinet. 2025 Feb;64(2):173-192. doi: 10.1007/s40262-024-01444-6. Epub 2024 Dec 7. Clin Pharmacokinet. 2025. PMID: 39644458 Free PMC article. Review.
References
-
- US Food and Drug Administration (FDA). Best Pharmaceuticals for Children Act and Pediatric Research Equity Act. Status report to Congress. https://www.fda.gov/media/99184/download. Accessed July 1, 2016.
-
- US Food and Drug Administration (FDA). How to comply with the Pediatric Research Equity Act. https://www.fda.gov/media/72274/download. Accessed September 1, 2005.
-
- Sachs AN, Avant D, Lee CS, Rodriguez W, Murphy MD. Pediatric information in drug product labeling. JAMA. 2012;307:1914-1915.
-
- Lynne P. Yao. Pediatric drug development: moving toward the best pharmaceuticals for children. Pediatric Drug Development Workshop. March 24, 2017. American Course on Drug Development and Regulatory Sciences.
-
- Momper JD, Mulugeta Y, Burckart GJ. Failed pediatric drug development trials. Clin Pharmacol Ther. 2015;98:245-251.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous